Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to marketnews2026-02-24T11:37:17+00:00February 24th, 2026|Endpoints News|
‘Ukrainians are a strong nation – we persevere’: Four years on scientists remain resilient in face of adversitynews2026-02-24T09:30:00+00:00February 24th, 2026|Chemistry World|
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic pushnews2026-02-24T08:30:05+00:00February 24th, 2026|Endpoints News|
Hims reports 2025 earnings, shares details on GLP-1 pill decisionsnews2026-02-24T08:00:50+00:00February 24th, 2026|Endpoints News|
